Wulff Hansen & CO. Lowers Position in Pfizer Inc. (NYSE:PFE)

Wulff Hansen & CO. cut its holdings in Pfizer Inc. (NYSE:PFE) by 8.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,314 shares of the biopharmaceutical company’s stock after selling 900 shares during the period. Wulff Hansen & CO.’s holdings in Pfizer were worth $247,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. State Street Corp grew its holdings in shares of Pfizer by 1.2% in the third quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company’s stock valued at $8,405,930,000 after acquiring an additional 3,405,539 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pfizer by 1.6% in the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock valued at $3,392,342,000 after acquiring an additional 1,855,419 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares in the last quarter. Finally, Van ECK Associates Corp grew its holdings in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after acquiring an additional 4,726,549 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 1.0 %

NYSE:PFE opened at $26.31 on Wednesday. The company has a market cap of $149.09 billion, a P/E ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.61. The stock’s fifty day moving average price is $26.21 and its two-hundred day moving average price is $27.09. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the business posted $0.10 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.